Results 1 to 10 of about 22 (22)

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

Cancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang, Qingyuan Zhang, Tao Sun, Huiping Li, Ying Cheng, Zhongsheng Tong, Huihui Li, Wei Li, Jingfen Wang, Yuee Teng, Xinhong Wu, Jing Cheng, Zhendong Chen, Zhengqiu Zhu, Li Wang, Mingming Liu, Xianghui Duan, Lingmei Xu, Binghe Xu   +18 more
wiley   +1 more source

ESPGHAN/NASPGHAN guidelines for treatment of irritable bowel syndrome and functional abdominal pain‐not otherwise specified in children aged 4–18 years

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Abdominal pain related disorders of gut–brain interaction (AP‐DGBIs) such as irritable bowel syndrome (IBS) and functional abdominal pain‐not otherwise specified (FAP) are common conditions in children, significantly impacting quality of life.
Jip Groen, Morris Gordon, Ashish Chogle, Marc Benninga, Rachel Borlack, Osvaldo Borrelli, Anil Darbari, Jernej Dolinsek, Julie Khlevner, Carlo Di Lorenzo, Hannibal Person, Rinarani Sanghavi, Julie Snyder, Nikhil Thapar, Arine Vlieger, Vasiliki Sinopoulou, Merit Tabbers, Miguel Saps   +17 more
wiley   +1 more source

Breathing and balance: Clinical insights and management strategies of respiratory acid‐base disorders

Nutrition in Clinical Practice, EarlyView.
Abstract Respiratory acidosis and alkalosis are two of the four main acid‐base processes encountered in clinical practice. These two processes are tightly balanced by breathing. Identification and management of respiratory acid‐base disorders are important for clinicians, particularly when caring for patients with underlying pulmonary and neurological ...
Anne M. Tucker, Tami N. Johnson
wiley   +1 more source

Treatment Experience Using a Micro‐Induction Buprenorphine Protocol for Chronic Pain in Pediatric Sickle Cell Disease

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with sickle cell disease (SCD) experience painful vaso‐occlusive episodes that increase with age; a subset develops chronic pain (CP). CP is usually managed with acute pain management guidelines despite evidence of ineffectiveness.
Ashwin Patel, Grace Kalmus, Carlton Dampier, Ifeyinwa Osunkwo, Tamara New, Beatrice Gee, Elna Saah   +6 more
wiley   +1 more source

European Consensus on Malabsorption—UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN

United European Gastroenterology Journal, EarlyView.
ABSTRACT Malabsorption is a complex and multifaceted condition characterised by the defective passage of nutrients into the blood and lymphatic streams. Several congenital or acquired disorders may cause either selective or global malabsorption in both children and adults, such as cystic fibrosis, exocrine pancreatic insufficiency (EPI), coeliac ...
Marco Vincenzo Lenti, Heinz Florian Hammer, Ilja Tacheci, Rosa Burgos, Stephane Schneider, Anastasiou Foteini, Aleksejs Derovs, Jutta Keller, Ilse Broekaert, Marianna Arvanitakis, Dan Lucian Dumitrascu, Oscar Segarra‐Cantón, Željko Krznarić, Juris Pokrotnieks, Gonçalo Nunes, Johann Hammer, Loris Pironi, Marc Sonyi, Cristina Maria Sabo, Juan Mendive, Adrien Nicolau, Jernej Dolinsek, Denisa Kyselova, Lucrezia Laterza, Antonio Gasbarrini, Teodora Surdea‐Blaga, Jorge Fonseca, Christos Lionis, Gino Roberto Corazza, Antonio Di Sabatino   +29 more
wiley   +1 more source

Opportunities and Challenges of Population Pharmacogenomics

Annals of Human Genetics, EarlyView.
ABSTRACT Pharmacological responses can vary significantly among patients from different ethnogeographic backgrounds. This variability can, at least in part, be attributed to population‐specific genetic patterns in genes involved in drug absorption, distribution, metabolism, and excretion, as well as in genes associated with drug‐induced toxicity ...
Yitian Zhou, Yoomi Park, Mahamadou D. Camara, Volker M. Lauschke   +3 more
wiley   +1 more source

When, which and how to switch: Navigating JAK inhibitors in myelofibrosis

British Journal of Haematology, EarlyView.
Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi‐naïve and for those who have previously been treated with a JAKi.
Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila   +2 more
wiley   +1 more source

Pyrotinib and Nab‐Paclitaxel in HER2‐Positive Breast Cancer (PANHER Trial): A Prospective, Single‐Arm, Phase II Trial

Cancer Science, EarlyView.
In this multicenter, single‐arm, open‐label phase II trial, patients with HER2‐positive breast cancer who had previously received chemotherapy with taxanes or anthracyclines were enrolled to receive pyrotinib combined with nab‐paclitaxel, and the results demonstrated promising efficacy with an acceptable safety profile.
Huan Li, Min Yan, Zhaohui Li, Xiujie Cui, Xuening Ji, Fengqi Fang, Yuyang Zhang, Yan Wang, Xiangyu Guo, Mingxi Jing, Zhichao Gao, Hui Cao, Fangyuan Dong, Jie Wu, Cui Jiang, Yangyang Duan, Xiaorui Li, Yujun Jiang, Lei Jiang, Ying E, Yufeng Jia, Liang Zhang, Pai Peng, Tao Sun   +23 more
wiley   +1 more source

The Burden of Fecal Incontinence: Evaluating the Societal Impact in Terms of Economic Burden and Health‐Related Quality of Life

Neurogastroenterology &Motility, EarlyView.
Fecal incontinence imposes significant societal costs (€2424 per patient per quarter) and negatively affects HRQoL (mean score 0.72). Unemployed patients face higher costs and lower HRQoL. These findings highlight the need for targeted management strategies and resource allocation to mitigate the economic and personal burden of FI.
Sadé L. Assmann, Merel L. Kimman, Stéphanie O. Breukink, Daniel Keszthelyi   +3 more
wiley   +1 more source

Drug Survival of Drugs Recommended for Irritable Bowel Syndrome: A Retrospective Observational Study

Neurogastroenterology &Motility, EarlyView.
ABSTRACT Background There is limited data on how drugs prescribed for functional bowel disorders are re‐prescribed in clinical practice. This study aimed to investigate drug survival rates of different irritable bowel syndrome (IBS) treatments among patients referred to a gastroenterologist.
Alice Sandberg‐Janzon, Pontus Karling
wiley   +1 more source